Normal tissue tolerance to intraoperative radiotherapy.
Much experimental evidence has been accumulated assessing the tolerance of various tissues to IORT, and much of the tolerance data have resulted from the use of canine models. Guidelines of IORT tissue tolerance established in experimental models have been used in the clinical application of IORT at numerous institutions. Although the radiotolerance of differing tissues can vary among species, sufficient clinical experience has accumulated to validate the canine tissue tolerance model as representative of human tissue responses to IORT. Cellular effects from radiation principally stem from direct damage to DNA, and thus proliferating tissues are among the most radiosensitive, with arrested or abnormal cell division. These tissues can manifest striking early toxicity, reflecting the rate of cell division that is affected by the radiation. Irradiation of nonproliferating or slowly proliferating tissues may show little or no early toxicity, but late effects can be manifested to considerable and varying degrees. In much of this late toxicity, pathologic changes develop from progressive ischemia, brought about by the gradual obliteration of small blood vessels. Irradiated endothelium often becomes replaced by a thickened fibrous layer, which, in small vessels, leads to occlusion and ischemic necrotic changes in the supplied tissue. In larger vessels, fibrosis can lead to wall weakening and aneurysmal dilatation, rupture, or thrombosis. The common denominator, then, of radiation damage to many tissues is related to vascular effects. Although the tolerance to IORT-induced toxicity can vary considerably among tissues, doses ranging to 25 Gy can generally be tolerated without significant toxicity. Vital areas where IORT dose must be carefully monitored include critical vasculature, gastrointestinal viscera, ureter, significant motor or sensory nerve trunks, and central nervous system structures. Higher doses can generally be delivered safely to anatomic areas at risk for tumor that are at a distance from sensitive organs or tissues. The general principle providing the rationale of IORT should always be practiced: maximize the radiation dose to the tumor and tumor-harboring tissues while minimizing dose exposure to surrounding normal tissues.
Sindelar
William F
WF
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
Kinsella
Timothy J
TJ
D000818:Animals; D002319:Cardiovascular System / Q000528:radiation effects; D003131:Combined Modality Therapy; D004064:Digestive System / Q000528:radiation effects; D004285:Dogs; D004307:Dose-Response Relationship, Radiation; D006801:Humans; D007432:Intraoperative Period; D023421:Models, Animal; D009141:Musculoskeletal System / Q000528:radiation effects; D009420:Nervous System / Q000528:radiation effects; D011829:Radiation Dosage; D011836:Radiation Tolerance / Q000502:physiology*; D018714:Radiotherapy, Adjuvant / Q000379:methods*; D012137:Respiratory System / Q000528:radiation effects; D013514:Surgical Procedures, Operative; D014551:Urinary Tract / Q000528:radiation effects